GALT - NASDAQ
Galectin Therapeutics Inc.
$2.35
+1.1%Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
At a Glance
Live SnapshotNo Investing Cash Flow Data
GALT has not reported any investing cash flow values in the available annual periods.
Galectin Therapeutics Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Galectin Therapeutics Inc. Cash Flow Statement
GALT • NASDAQ
| Galectin Therapeutics Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
-30.8M | -47M | -41.1M | -38.8M | -30.5M | -23.5M | -13.3M | -13.9M | -16.2M | -21.4M | -20M | -15.8M | -12.1M | -9.9M | -10.9M | -5.6M | -7.5M | -3.2M | -9.4M | -3.2M | |
53K | 37K | 33K | 32K | 41K | 36K | 35K | 0.0 | 1K | 7K | 7K | 10K | 12K | 9K | 9K | 12K | 37K | 49K | 64K | 67K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -616K | -416K | |
1.7M | 2.4M | 2.3M | 2.9M | 2.1M | 1.8M | 1.7M | 4.4M | 1.1M | 2.5M | 3.4M | 4.1M | 3.8M | 2.8K | 3.2M | 1.9M | 1.6M | 697K | 0.0 | 0.0 | |
4.6M | 512K | 1.1M | -147K | 351K | 87K | 87K | 348K | 45K | 0.0 | 0.0 | 400K | 0.0 | 3M | 524K | 1.3M | 1.5M | -2.1M | 4.3M | -2.8M | |
609K | 2.3M | 4.7M | 5M | 3.8M | 942K | 641K | -1.1M | -804K | 2.5M | -363K | -1.1M | 803K | -626K | 1.5M | -683K | 399K | -126K | 184K | -406K | |
-23.9M | -41.8M | -33M | -31.1M | -24.3M | -20.6M | -10.8M | -10.2M | -15.9M | -16.4M | -17M | -12.4M | -7.5M | -7.5M | -5.7M | -3.1M | -3.9M | -4.7M | -5.5M | -6.8M | |
INVESTING ACTIVITIES | ||||||||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -5K | -5K | -5K | (0.0) | (0.0) | -2K | -42K | -98K | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -400K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -400K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -5M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 5M | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -400K | 400K | 69K | 69K | -10K | 0.0 | 0.0 | 11K | -11K | -138K | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -400K | (64K) | (64K) | -15K | (0.0) | (0.0) | (9K) | (4.9M) | -5.2M | |
FINANCING ACTIVITIES | ||||||||||||||||||||
5.5M | 1.2M | 0.0 | 0.0 | 6.8M | 263K | 50.5M | 15.4M | 3.6M | 5.9M | 13.7M | 29.3M | 3.8M | 10.4M | 0.0 | 0.0 | 0.0 | 3.4M | 0.0 | 0.0 | |
21M | 30M | 30M | 10M | 30M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 200K | -555K | 8.3M | |
(0.0) | -91K | (0.0) | (0.0) | -171K | -137K | -394K | -915K | -1.2M | -741K | -943K | -943K | (0.0) | (0.0) | -1.5M | -2.1M | -209K | (0.0) | (0.0) | (0.0) | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -1.3M | (0.0) | (0.0) | (0.0) | |
0.0 | 91K | 10M | 0.0 | 171K | 137K | 0.0 | 915K | 1.2M | 741K | 943K | 3.1M | 4.8M | 0.0 | 7.6M | 7.3M | 9K | 0.0 | 1.6M | 0.0 | |
26.5M | 31.2M | 40M | 10M | 36.8M | 263K | 50.1M | 15.4M | 3.6M | 5.9M | 13.7M | 31.5M | 8.6M | 10.4M | 6.2M | 8.7M | 3.8M | 3.7M | 1.1M | 8.3M | |
CASH FLOW SUMMARY | ||||||||||||||||||||
2.6M | -10.5M | 7.1M | -21.1M | 12.5M | -20.3M | 39.2M | 5.2M | -12.3M | -10.5M | -3.3M | 18.6M | 1.1M | 3M | 506K | 5.6M | -67K | -1M | 546K | -3.7M | |
15.1M | 25.7M | 18.6M | 39.6M | 27.1M | 47.5M | 8.3M | 3.1M | 15.4M | 25.8M | 29.1M | 10.5M | 9.4M | 6.4M | 5.9M | 251K | 318K | 1.3M | 773K | 4.5M | |
17.7M | 15.1M | 25.7M | 18.6M | 39.6M | 27.1M | 47.5M | 8.3M | 3.1M | 15.4M | 25.8M | 29.1M | 10.5M | 9.4M | 6.4M | 5.9M | 251K | 318K | 1.3M | 773K | |
-23.9M | -41.8M | -33M | -31.1M | -24.3M | -20.6M | -10.8M | -10.2M | -15.9M | -16.4M | -17M | -12.4M | -7.5M | -7.5M | -5.7M | -3.1M | -3.9M | -4.7M | -5.5M | -6.9M |
SEC Filings
GALT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 15, 2026 | May 15, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 15, 2026 | March 31, 2026 | 2026 | |
S-3 S-3 N/A | March 31, 2026 | March 31, 2026 | ||
8-K 8-K 2026 N/A | March 31, 2026 | March 31, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 31, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 17, 2026 | March 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 21, 2026 | January 16, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 10, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 19, 2025 | December 19, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 08, 2025 | December 03, 2025 | 2025 |
Related Guides
Continue your GALT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.